PHARMACEUTICAL ASSESSMENT OF GYNAECOLOGICAL POWDERS WITH SODIUM ALGINATE CONTAINING A LACTIC ACID-CHITOSAN COMPLEX

• Authors: Katarzyna Małolepsza-Jarmołowska
• Languages of publication: EN

Abstracts

EN

The insufficient duration of the drug’s contact with the vaginal mucosa does not provide adequate pH, conditioning the physiological biocenosis of the organ. This effect is hampered by numerous anatomic and physiological conditions which do not facilitate prolonged contact of the drug with the application site. This study has shown the impact of the used excipients and the ratio of lactic acid to chitosan on pH, dynamic viscosity and adhesiveness of methylcellulose gels obtained from powders. The addition of sodium alginate and excipients to these complexes allows various formulations to be obtained over a wide range of pH. Rheological investigations revealed an increase in the dynamic viscosity of preparations containing lactic acid complexed with chitosan and sodium alginate in comparison to gels without sodium alginate. Studies of the work of adhesion showed the effect of glycerol, 1,2-propylene glycol and their concentrations on the value of the work of adhesion.

Keywords

EN

anti-inflammatory drugs; hydrophilic powders; lactic acid complexed with chitosan; physiological environment of the vagina; vaginal infections.; vaginal mucosa

Discipline

• PHARMACOLOGY: PHARMACOLOGY

• Publisher: Sieć Badawcza Łukasiewicz - Polskie Towarzystwo Chitynowe
• Journal: Progress on Chemistry and Application of Chitin and its Derivatives
• Year: 2018
• Volume: 23
• Pages: 130 - 139

Contributors

author

Katarzyna Małolepsza-Jarmołowska

• Department of Drugs Form Technology, Faculty of Pharmacy, The “Silesian Piasts” Memorial Medical University of Wroclaw,

References

• [1] Schwebke JR; (2009) New Concepts in the Etiology of Bacterial Vaginosis. Curr. Infect. Dis. Rep. 11, 143 – 147. DOI: 10.1007/s11908-009-0021-7
• [2] Brandt M, Abels C, May T, Lohmann K, Schmidts – Winkler I, Hoyme UB; (2008) Intravaginally applied metronidazole is as effective as orally applied in the treatment of bacterial vaginosis, but exhibits significantly less side effects. Eur. J. Obstet. Gynecol. Reprod. Biol. 141, 158 – 162. doi.org/10.1016/j.ejogrb.2008.07.022
• [3] Donders GGG, Larson PG, Platz – Christensen JJ, Hallen A, Meijden W, Wölner – Hanssen P; (2009) Variability in diagnosis of clue cells, lactobacillary grading and white blood cells in vaginal wet smears with conventional bright light and phase contrast microscopy. Eur. J. Obstet. Gynecol. Reprod. Biol. 145, 109 – 112. doi.org/10.1016/j.ejogrb.2009.04.012
• [4] Kubis AA, Małolepsza-Jarmołowska K; (1996) Studies on gynecological hydrophiling preparations comprising lactic acid. Part 1: Effects of lactic acid and hydrophiling agents on physical and chemical properties of methylcellulose gels. Pharmazie 51, 989 – 990.
• [5] Małolepsza-Jarmołowska K, Kubis AA; (1999) Studies on gynecological hydrophilic lactic acid preparations. Part 2: Effects of Eudragit® E-100 on properties of methylcellulose gels. Pharmazie 54, 441 – 443.
• [6] Małolepsza-Jarmołowska K, Kubis AA; (2000) Studies on gynaecological hydrophilic lactic acid preparations. Part 3: Effects of chitosan on the properties of methylcellulose gels. Pharmazie 55, 610 – 611.
• [7] Małolepsza-Jarmołowska K, Kubis AA; (2001) Studies on gynaecological hydrophilic lactic acid preparations. Part 4: Effects of polyvinyl pyrrolidone K-90 on properties of methylcellulose gels. Pharmazie 56, 160 – 162.
• [8] Małolepsza-Jarmołowska K, Kubis AA, Hirnle L; (2003) Studies on gynaecological hydrophilic lactic acid preparations. Part 5: The use of Eudragit® E-100 as lactic acid carrier in intravaginal tablets. Pharmazie 58, 260 – 262.
• [9] Małolepsza-Jarmołowska K, Kubis AA, Hirnle L; (2003) Studies on gynaecological hydrophilic lactic acid preparations. Part 6: Use of Eudragit® E-100 as lactic acid carrier in intravaginal tablets. Pharmazie 58, 334-336.
• [10] Małolepsza-Jarmołowska K; (2006) Studies on gynaecological hydrophilic lactic acid preparations. Part 7: Use of chitosan as lactic acid carrier in intravaginal tablets (globuli vaginales). Pharmazie 61, 780 - 782.
• [11] Małolepsza-Jarmołowska K; (2007) Studies on gynaecological hydrophilic lactic acid preparations. Part 8: Use of chitosan as lactic acid carrier in intravaginal tablets. Acta Pol. Pharm. 64, 69 - 72.
• [12] Małolepsza-Jarmołowska K; (2010) The effect of poloxamer 407 on the properties of hydrophilic gels containing lactic acid complexed with chitosan. Monograph vol. XV ed. by M. Jaworska „Progress on Chemistry and Application of Chitin and Its Derivatives“ 15, 143-148.
• [13] Małolepsza-Jarmołowska K; (2014) Research of pharmaceutical properties of hydrophilic powders containing lactic acid complexed with chitosan „Progress on Chemistry and Application of Chitin and Its Derivatives“ 14, 79-86 vol. XIX, ed. by M. Jaworska doi:10.15259/PCACD.19.09
• [14] Małolepsza-Jarmołowska K; (2017) Influence of a pectin on the properties of hydrophilic powders containing a lactic acid-chitosan complex „Progress on Chemistry and Application of Chitin and Its Derivatives“ 17, 135-142 vol. XXII, ed. by M. Jaworska doi:10.15259/PCACD.22.13

• Document Type: article